Guggenheim Raises Savara (NASDAQ:SVRA) Price Target to $10.00

Savara (NASDAQ:SVRA) had its target price raised by Guggenheim from $8.00 to $10.00 in a report issued on Thursday morning, Benzinga reports. Guggenheim currently has a buy rating on the stock.

Other research analysts have also issued research reports about the company. Piper Sandler raised their price objective on Savara from $7.00 to $16.00 and gave the company an overweight rating in a research report on Monday, March 4th. Oppenheimer raised their price target on Savara from $11.00 to $15.00 and gave the company an outperform rating in a report on Wednesday. HC Wainwright lifted their price objective on Savara from $6.00 to $10.00 and gave the stock a buy rating in a research note on Thursday. JMP Securities reiterated a market outperform rating and set a $8.00 target price on shares of Savara in a research report on Monday, May 6th. Finally, Evercore ISI reduced their price target on shares of Savara from $10.00 to $7.00 and set an outperform rating on the stock in a research report on Thursday, May 16th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus price target of $11.00.

Savara Price Performance

NASDAQ SVRA opened at $4.03 on Thursday. The company has a quick ratio of 14.90, a current ratio of 14.90 and a debt-to-equity ratio of 0.22. Savara has a 52 week low of $2.63 and a 52 week high of $5.70. The firm has a market capitalization of $556.91 million, a P/E ratio of -10.89 and a beta of 0.70. The company has a 50-day moving average price of $4.30 and a 200-day moving average price of $4.63.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities research analysts anticipate that Savara will post -0.41 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Several large investors have recently modified their holdings of SVRA. Wellington Management Group LLP purchased a new position in Savara during the fourth quarter worth $9,683,000. Superstring Capital Management LP bought a new stake in shares of Savara in the 4th quarter worth about $3,827,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Savara by 30.9% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock worth $30,008,000 after acquiring an additional 1,874,000 shares during the last quarter. Polar Capital Holdings Plc purchased a new position in shares of Savara during the 3rd quarter worth about $3,780,000. Finally, Jennison Associates LLC grew its holdings in Savara by 128.0% during the 4th quarter. Jennison Associates LLC now owns 8,815,358 shares of the company’s stock valued at $41,432,000 after purchasing an additional 4,948,596 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.